Variation of prostate-specific antigen value in men and risk of high-grade prostate cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial study - Abstract

OBJECTIVE: To investigate variations in prostate-specific antigen (PSA) levels among men with an initial normal PSA level in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial study.

METHODS: Data were extracted from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial study data set on all men in the interventional arm, with 2 tests performed in a period of < 2 years and with an initial result of the first test < 4 ng/mL. The range of variation between first and second tests was computed. Risks of cancer stratified on Gleason score were computed using logistic regression.

RESULTS: A total of 31,286 men had 2 PSA tests within 2 years and with an initial value < 4 ng/mL. From the first to the second test, the median variation of PSA levels was 3.4% (interquartile range, -15% to +26%). The variation in PSA value was not associated with the delay between the first and the second test (P = .36), age (P = .16), body mass index (P = .41), and race (P = .12). A total of 2,781 prostate cancers were diagnosed during follow-up. Adjusting for age and initial PSA level, the risk of prostate cancer increased linearly with increasing PSA level at the second test, with an odds ratio of 1.079 (95% confidence interval, 1.058-1.101) for each percent increase in PSA level. However, the variation in PSA was not associated with a higher Gleason score (P = .95 for level variations in cancer of Gleason score < 7 vs ≥7).

CONCLUSION:Although an increase in PSA level over time is associated with increased risk of prostate cancer, this association is not related to more aggressive tumors.

Written by:
Boniol M, Autier P, Perrin P, Boyle P.   Are you the author?
University of Strathclyde Institute of Global Public Health at iPRI, Lyon, France; International Prevention Research Institute (iPRI), Lyon, France; Department of Urology, CHU Lyon-Sud, Pierre-Benite, France.  

Reference: Urology. 2015 May;85(5):1117-22.
doi: 10.1016/j.urology.2015.02.013

PubMed Abstract
PMID: 25917734 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.